These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9436457)

  • 1. [Molecular biology and immunology of acetylcholine receptor in relation to myasthenia gravis].
    Takamori M; Komai K; Iwasa K; Yoshikawa H
    Nihon Rinsho; 1997 Dec; 55(12):3315-21. PubMed ID: 9436457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma.
    Mygland A; Tysnes OB; Matre R; Volpe P; Aarli JA; Gilhus NE
    Ann Neurol; 1992 Oct; 32(4):589-91. PubMed ID: 1333745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ; Oshima M; Deitiker P
    Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides.
    Fujii Y; Lindstrom J
    J Immunol; 1988 Mar; 140(6):1830-7. PubMed ID: 2450133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biochemical approaches to neuromuscular junction disorders].
    Takamori M
    Rinsho Shinkeigaku; 1996 Dec; 36(12):1363-4. PubMed ID: 9128412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A joint undertaking by molecular biology and immunology in search for the pathogenesis of neuromuscular synaptic disorders].
    Takamori M
    Nihon Rinsho; 1997 Dec; 55(12):3106-13. PubMed ID: 9436419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Myasthenia gravis: pathogenesis and therapeutic approach on the basis of molecular structure and immunogenicity of acetylcholine receptor].
    Takamori M
    Nihon Rinsho; 1994 Nov; 52(11):3038-45. PubMed ID: 7996707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous thymoma rat as a model for myasthenic weakness caused by anti-ryanodine receptor antibodies.
    Iwasa K; Komai K; Takamori M
    Muscle Nerve; 1998 Dec; 21(12):1655-60. PubMed ID: 9843065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antibodies in myasthenia gravis].
    Eymard B
    Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes.
    Nagvekar N; Moody AM; Moss P; Roxanis I; Curnow J; Beeson D; Pantic N; Newsom-Davis J; Vincent A; Willcox N
    J Clin Invest; 1998 May; 101(10):2268-77. PubMed ID: 9593783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 17-Mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis.
    Yoshikawa H; Lambert EH; Walser-Kuntz DR; Yasukawa Y; McCormick DJ; Lennon VA
    J Immunol; 1997 Aug; 159(3):1570-7. PubMed ID: 9233656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmunity against the ryanodine receptor in myasthenia gravis.
    Skeie GO; Lunde PK; Sejersted OM; Mygland A; Aarli JA; Gilhus NE
    Acta Physiol Scand; 2001 Mar; 171(3):379-84. PubMed ID: 11412151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance.
    Romi F; Skeie GO; Gilhus NE; Aarli JA
    Arch Neurol; 2005 Mar; 62(3):442-6. PubMed ID: 15767509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis.
    Kawanami S; Tsuji R; Oda K
    Ann Neurol; 1984 Feb; 15(2):195-200. PubMed ID: 6367620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes.
    Brocke S; Brautbar C; Steinman L; Abramsky O; Rothbard J; Neumann D; Fuchs S; Mozes E
    J Clin Invest; 1988 Dec; 82(6):1894-900. PubMed ID: 2461962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies.
    Romi F; Skeie GO; Aarli JA; Gilhus NE
    Arch Neurol; 2000 Nov; 57(11):1596-600. PubMed ID: 11074791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro.
    Skeie GO; Mygland A; Treves S; Gilhus NE; Aarli JA; Zorzato F
    Muscle Nerve; 2003 Jan; 27(1):81-9. PubMed ID: 12508299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera.
    Tzartos SJ; Sophianos D; Efthimiadis A
    J Immunol; 1985 Apr; 134(4):2343-9. PubMed ID: 3973387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of experimental autoimmune myasthenia gravis by major histocompatibility complex class II competitor peptides results not only in a suppressed but also in an altered immune response.
    Wauben MH; Hoedemaekers AC; Graus YM; Wagenaar JP; van Eden W; de Baets MH
    Eur J Immunol; 1996 Dec; 26(12):2866-75. PubMed ID: 8977279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-ryanodine receptor-positive acetylcholine receptor-negative myasthenia gravis: evidence of impaired excitation-contraction coupling.
    Imai T; Tsuda E; Toyoshima T; Yoshikawa H; Motomura M; Shimohama S
    Muscle Nerve; 2011 Feb; 43(2):294-5. PubMed ID: 21254099
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.